CAR T cells produced in vivo to treat cardiac injury

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed. Please read our Terms of Service before submitting your own eLetter. No eLetters have been published for this article yet. Chimeric antigen receptor T cells treating myocardial fibrosis has the significant advantages of systematic design, low toxicity and risk of lymphatic depletion, ability to titrate doses, and virus-free to eliminate the risk of host genomic alterations. Typical LNPs components phospholipids own the potential capacities to modulate the signal transduction both extra- and intra-celluar, this would possibly impact the core procedure of this research: trogocytosis. Also, LNP systems can be limited by low drug loading and biodistribution that results in high uptake to the liver and spleen. These above factors will cause the false-effect of CAR T therapies. Moreover, another excellent nanomaterial for drug delivery, fullerene, shou

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed. Please read our Terms of Service before submitting your own eLetter. No eLetters have been published for this article yet. Chimeric antigen receptor T cells treating myocardial fibrosis has the significant advantages of systematic design, low toxicity and risk of lymphatic depletion, ability to titrate doses, and virus-free to eliminate the risk of host genomic alterations. Typical LNPs components phospholipids own the potential capacities to modulate the